| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institute of Experimental Immunology and
Laboratory for Special Techniques, Department of Pathology, University Hospital, Zurich, Switzerland; and
Novartis Pharma AG, Basel, Switzerland
FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) prolongs survival of solid organ allografts in animal models. Mechanisms of FTY720 immunomodulation were studied in mice infected with lymphocytic choriomeningitis virus (LCMV) to assess T cell responses or with vesicular stomatitis virus to evaluate Ab responses. Oral FTY720 (0.3 mg/kg/day) did not affect LCMV replication and specific CTL and B cells were induced and expanded normally. Moreover, the anti-viral humoral immune responses were normal. However, FTY720 treatment showed first a shift of overall distribution of CTL from the spleen to peripheral lymph nodes and lymphocytopenia was observed. This effect was reversible within 7–21 days. Together with unimpaired T and B cell memory after FTY720 treatment, this finding rendered enhancement of lymphocyte apoptosis by FTY720 in vivo unlikely. Secondly, the delayed-type hypersensitivity reaction to a viral MHC class I-presented peptide was markedly reduced by FTY720. These results were supported by impaired circulation of LCMV specific TCR transgenic effector lymphocytes in the peripheral blood and reduced numbers of tissue infiltrating CTL in response to delayed-type hypersensitivity reaction. Thirdly, in a CD8+ T cell-mediated diabetes model in a transgenic mouse expressing the LCMV glycoprotein in the islets of the pancreas, FTY720 delayed or prevented disease by reducing islet-infiltrating CTL. Thus, FTY720 effectively reduced recirculation of CD8+ effector T cells and their recruitment to peripheral lesions without affecting the induction and expansion of immune responses in secondary lymphoid organs. These properties may offer the potential to treat ongoing organ-specific T cell-mediated immunopathologic disease.
This article has been cited by other articles:
|
|
 |
|
  M. Mehling, V. Brinkmann, J. Antel, A. Bar-Or, N. Goebels, C. Vedrine, C. Kristofic, J. Kuhle, R.L.P. Lindberg, and L. Kappos FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology, October 14, 2008; 71(16): 1261 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Marsolais, B. Hahm, K. H. Edelmann, K. B. Walsh, M. Guerrero, Y. Hatta, Y. Kawaoka, E. Roberts, M. B. A. Oldstone, and H. Rosen Local Not Systemic Modulation of Dendritic Cell S1P Receptors in Lung Blunts Virus-Specific Immune Responses to Influenza Mol. Pharmacol., September 1, 2008; 74(3): 896 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daniel, N. Sartory, N. Zahn, G. Geisslinger, H. H. Radeke, and J. M. Stein FTY720 Ameliorates Th1-Mediated Colitis in Mice by Directly Affecting the Functional Activity of CD4+CD25+ Regulatory T Cells J. Immunol., February 15, 2007; 178(4): 2458 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kabashima, N. M. Haynes, Y. Xu, S. L. Nutt, M. L. Allende, R. L. Proia, and J. G. Cyster Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism J. Exp. Med., November 27, 2006; 203(12): 2683 - 2690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis N. Engl. J. Med., September 14, 2006; 355(11): 1124 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schmouder, D. Serra, Y. Wang, J. M. Kovarik, J. DiMarco, T. L. Hunt, and M.-C. Bastien FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects. J. Clin. Pharmacol., August 1, 2006; 46(8): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fujii, T. Kanai, Y. Nemoto, S. Makita, S. Oshima, R. Okamoto, K. Tsuchiya, T. Totsuka, and M. Watanabe FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis Am J Physiol Gastrointest Liver Physiol, August 1, 2006; 291(2): G267 - G274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Awad, H. Ye, L. Huang, L. Li, F. W. Foss Jr., T. L. Macdonald, K. R. Lynch, and M. D. Okusa Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1516 - F1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, Y. Chen, R. L. Fairchild, P. S. Heeger, and A. Valujskikh Lymphoid Sequestration of Alloreactive Memory CD4 T Cells Promotes Cardiac Allograft Survival J. Immunol., January 15, 2006; 176(2): 770 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Habicht, M. R. Clarkson, J. Yang, J. Henderson, V. Brinkmann, S. Fernandes, M. Jurewicz, X. Yuan, and M. H. Sayegh Novel Insights into the Mechanism of Action of FTY720 in a Transgenic Model of Allograft Rejection: Implications for Therapy of Chronic Rejection J. Immunol., January 1, 2006; 176(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sawicka, G. Dubois, G. Jarai, M. Edwards, M. Thomas, A. Nicholls, R. Albert, C. Newson, V. Brinkmann, and C. Walker The Sphingosine 1-Phosphate Receptor Agonist FTY720 Differentially Affects the Sequestration of CD4+/CD25+ T-Regulatory Cells and Enhances Their Functional Activity J. Immunol., December 15, 2005; 175(12): 7973 - 7980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. I. Singer, M. Tian, L. A. Wickham, J. Lin, S. S. Matheravidathu, M. J. Forrest, S. Mandala, and E. J. Quackenbush Sphingosine-1-Phosphate Agonists Increase Macrophage Homing, Lymphocyte Contacts, and Endothelial Junctional Complex Formation in Murine Lymph Nodes J. Immunol., December 1, 2005; 175(11): 7151 - 7161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bandhuvula, Y. Y. Tam, B. Oskouian, and J. D. Saba The Immune Modulator FTY720 Inhibits Sphingosine-1-phosphate Lyase Activity J. Biol. Chem., October 7, 2005; 280(40): 33697 - 33700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Czeloth, G. Bernhardt, F. Hofmann, H. Genth, and R. Forster Sphingosine-1-Phosphate Mediates Migration of Mature Dendritic Cells J. Immunol., September 1, 2005; 175(5): 2960 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Halin, M. L. Scimone, R. Bonasio, J.-M. Gauguet, T. R. Mempel, E. Quackenbush, R. L. Proia, S. Mandala, and U. H. von Andrian The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches Blood, August 15, 2005; 106(4): 1314 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Vora, E. Nichols, G. Porter, Y. Cui, C. A. Keohane, R. Hajdu, J. Hale, W. Neway, D. Zaller, and S. Mandala Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement J. Leukoc. Biol., August 1, 2005; 78(2): 471 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Martinez, H. T. C. Kreuwel, W. L. Redmond, R. Trenney, K. Hunter, H. Rosen, N. Sarvetnick, L. S. Wicker, and L. A. Sherman CD8+ T Cell Tolerance in Nonobese Diabetic Mice Is Restored by Insulin-Dependent Diabetes Resistance Alleles J. Immunol., August 1, 2005; 175(3): 1677 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Lo, Y. Xu, R. L. Proia, and J. G. Cyster Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit J. Exp. Med., January 18, 2005; 201(2): 291 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Han, X. Zhang, G. Wang, H. Guan, G. Garcia, P. Li, L. Feng, and B. Zheng FTY720 suppresses humoral immunity by inhibiting germinal center reaction Blood, December 15, 2004; 104(13): 4129 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Welsch, L. W. A. Roth, J. F. Goetschy, and N. R. Movva Genetic, Biochemical, and Transcriptional Responses of Saccharomyces cerevisiae to the Novel Immunomodulator FTY720 Largely Mimic Those of the Natural Sphingolipid Phytosphingosine J. Biol. Chem., August 27, 2004; 279(35): 36720 - 36731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Yopp, S. Fu, S. M. Honig, G. J. Randolph, Y. Ding, N. R. Krieger, and J. S. Bromberg FTY720-Enhanced T Cell Homing Is Dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for Distinct Chemokine Compartments J. Immunol., July 15, 2004; 173(2): 855 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kunzendorf, E. Ziegler, and D. Kabelitz FTY720--the first compound of a new promising class of immunosuppressive drugs Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1677 - 1681. [Full Text] [PDF]
|
|
|
|
 |
|
 K Mayer, F Birnbaum, T Reinhard, A Reis, S Braunstein, F Claas, and R Sundmacher FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations Br. J. Ophthalmol., July 1, 2004; 88(7): 915 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Kovarik, R. L Schmouder, D. Barilla, M. Buche, M. Rouilly, S. Berthier, Y. Wang, C. Van Saders, T. Mayer, and A. B Gottlieb FTY720 and Cyclosporine: Evaluation for a Pharmacokinetic Interaction Ann. Pharmacother., July 1, 2004; 38(7): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kimura, A. M. Boehmler, G. Seitz, S. Kuci, T. Wiesner, V. Brinkmann, L. Kanz, and R. Mohle The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells Blood, June 15, 2004; 103(12): 4478 - 4486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Forrest, S.-Y. Sun, R. Hajdu, J. Bergstrom, D. Card, G. Doherty, J. Hale, C. Keohane, C. Meyers, J. Milligan, et al. Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 758 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kovarik, R. Schmouder, D. Barilla, G.-J. Riviere, Y. Wang, and T. Hunt Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects J. Clin. Pharmacol., May 1, 2004; 44(5): 532 - 537. [Abstract] [Full Text]
|
|
|
|
|
|
E. Sawicka, C. Zuany-Amorim, C. Manlius, A. Trifilieff, V. Brinkmann, D. M. Kemeny, and C. Walker Inhibition of Th1- and Th2-Mediated Airway Inflammation by the Sphingosine 1-Phosphate Receptor Agonist FTY720 J. Immunol., December 1, 2003; 171(11): 6206 - 6214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Billich, F. Bornancin, P. Devay, D. Mechtcheriakova, N. Urtz, and T. Baumruker Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases J. Biol. Chem., November 28, 2003; 278(48): 47408 - 47415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rosen, C. Alfonso, C. D. Surh, and M. G. McHeyzer-Williams Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist PNAS, September 16, 2003; 100(19): 10907 - 10912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Yopp, G. J. Randolph, and J. S. Bromberg Leukotrienes, Sphingolipids, and Leukocyte Trafficking J. Immunol., July 1, 2003; 171(1): 5 - 10. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Woltman and C. van Kooten Functional modulation of dendritic cells to suppress adaptive immune responses J. Leukoc. Biol., April 1, 2003; 73(4): 428 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujino, N. Funeshima, Y. Kitazawa, H. Kimura, H. Amemiya, S. Suzuki, and X.-K. Li Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 70 - 77. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Xie, N. Nomura, S. L. Koprak, E. J. Quackenbush, M. J. Forrest, and H. Rosen Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells J. Immunol., April 1, 2003; 170(7): 3662 - 3670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Brinkmann, M. D. Davis, C. E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, et al. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors J. Biol. Chem., June 7, 2002; 277(24): 21453 - 21457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, G. M. L. Meno-Tetang, K. Chiba, N. Arima, P. Heining, and W. J. Jusko Pharmacokinetics and Cell Trafficking Dynamics of 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Hydrochloride (FTY720) in Cynomolgus Monkeys after Single Oral and Intravenous Doses J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Budde, R. L. Schmouder, R. Brunkhorst, B. Nashan, P. W. Lucker, T. Mayer, S. Choudhury, A. Skerjanec, G. Kraus, and H. H. Neumayer First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1073 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bai, J. Liu, Y. Wang, S. Honig, L. Qin, P. Boros, and J. S. Bromberg L-Selectin-Dependent Lymphoid Occupancy Is Required to Induce Alloantigen-Specific Tolerance J. Immunol., February 15, 2002; 168(4): 1579 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Henning, L. Ohl, T. Junt, P. Reiterer, V. Brinkmann, H. Nakano, W. Hohenberger, M. Lipp, and R. Forster CC Chemokine Receptor 7-dependent and -independent Pathways for Lymphocyte Homing: Modulation by FTY720 J. Exp. Med., December 17, 2001; 194(12): 1875 - 1881. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
